Maryland SB562 allows pharmacists to enter into agreements with prescribers for treating opioid use disorders with controlled substances.

Maryland SB562 amends the state's Health Occupations law to allow licensed pharmacists to enter into prescriber-pharmacist agreements for treating opioid use disorders with controlled dangerous substances drug therapy. The bill requires pharmacists to complete relevant training, follow specific protocols, and submit agreements to the Board of Pharmacy. It also mandates that protocols require pharmacists to request data from the Prescription Drug Monitoring Program before initiating or modifying controlled dangerous substances therapy. The changes take effect July 1, 2026.

Maryland SB562 allows pharmacists to enter into agreements with prescribers for treating opioid use disorders with controlled substances.

Maryland SB562 amends the state's Health Occupations law to allow licensed pharmacists to enter into prescriber-pharmacist agreements for treating opioid use disorders with controlled dangerous substances drug therapy. The bill requires pharmacists to complete relevant training, follow specific protocols, and submit agreements to the Board of Pharmacy. It also mandates that protocols require pharmacists to request data from the Prescription Drug Monitoring Program before initiating or modifying controlled dangerous substances therapy. The changes take effect July 1, 2026.